시장보고서
상품코드
1786839

세계의 당뇨병성 케톤산증(DKA) 치료 시장 : 규모, 점유율, 동향, 산업 분석 보고서 - 치료 유형별, 용도별, 최종 사용자별, 지역별 시장 예측(2025-2034년)

Diabetic Ketoacidosis Treatment Market Size, Share, Trends, & Industry Analysis Report By Treatment Type, By Application (Pediatric and Adults), By End User, and By Region - Market Forecast, 2025-2034

발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 120 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최근 조사에 따르면 당뇨병성 케톤산증(DKA) 치료 시장 규모는 2034년까지 12억 9,208만 달러에 이를 전망입니다. 이 설문조사 보고서는 현재 시장 역학을 자세히 파악하고 향후 시장 성장에 대한 분석을 제공합니다.

당뇨병성 케톤산증(DKA) 치료는 1형 당뇨병 환자의 급성 당뇨병성 응급 상황에서 대사 불균형을 시정하는 데 필수적입니다. 표준 치료에는 고혈당과 산증을 안정시키기 위한 인슐린 정주, 주입 소생, 전해질 보충이 포함됩니다. 인슐린 아날로그, 연속 혈당 모니터링 기기, 실시간 전해질 관리의 진보는 병원, ICU, 외래 치료 환경에서의 치료 성적을 향상시키고 있습니다.

당뇨병성 케톤산증(DKA) 치료 시장의 성장은 주로 1형 당뇨병의 세계 유병률 증가와 급성기 의료 환경에서의 디지털 헬스 플랫폼의 채용 증가에 의해 초래됩니다. 게다가 외래 응급 인프라의 확대 및 지불자가 지원하는 분산형 치료 모델이 신흥 경제 국가 및 선진 경제 국가에서의 채용을 가속화하고 있습니다.

당뇨병성 케톤산증(DKA) 치료 시장 보고서 하이라이트

치료 유형별로 인슐린 요법이 2024년 시장을 독점했습니다. 이는 긴급 DKA 프로토콜에서 신속한 포도당 감소를 위한 제1선택 약물로서 지속적으로 사용되기 때문입니다.

용도별로는 성인 시장이 2024년 시장을 독점했습니다. 이 배경에는 성인 집단에서 인슐린 투여 누출, 병존 질환 및 당뇨병 관리 지연과 관련된 입원률 증가입니다.

최종 사용자별로 병원 부문은 2024년 시장을 석권했습니다. 이는 진보된 진단, 점적 요법 및 중증 치료 직원에 대한 접근을 통해 심각한 재발성 DKA 사례를 관리하는 종합적인 능력이 있기 때문입니다.

북미는 2024년 당뇨병성 케톤산증(DKA) 치료 시장의 대부분을 차지했으며, CGM의 보급, 인슐린 전달 시스템의 디지털화, 표준화된 치료 프로토콜의 준수가 시장의 리더십을 지원하고 있습니다.

아시아태평양은 1형 당뇨병의 이환율 증가 및 긴급 당뇨병 치료에 대한 공공 의료 투자로 인해 큰 시장 점유율을 차지하고 있습니다.

세계 주요 시장 기업은 Novo Nordisk A/S, Sanofi, Eli Lilly and Company, Becton, Dickinson and Company(BD), Dexcom, Inc., Medtronic plc, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Insulet Corporation, Tandem Diabetes Care, Inc. Ypsomed AG, Glenmark Pharmaceuticals Ltd. 등이 포함됩니다.

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 세계의 당뇨병성 케톤산증(DKA) 치료 시장 인사이트

  • 시장 현황
  • 당뇨병성 케톤산증(DKA) 치료 시장 역학
    • 성장 촉진요인 및 기회
      • 세계의 1형 당뇨병 유병률 상승
      • 급성기 케어에서 디지털 헬스 플랫폼의 통합
    • 성장 억제요인 및 과제
      • 급성기 케어 인프라의 고비용 부담
  • PESTEL 분석
  • 당뇨병성 케톤산증(DKA) 치료 시장 동향
  • 밸류체인 분석

제5장 세계의 당뇨병성 케톤산증(DKA) 치료 시장 : 치료 유형별

  • 주요 조사 결과
  • 서문
  • 인슐린 요법
  • 수분 보급
  • 전해질 보급

제6장 세계의 당뇨병성 케톤산증(DKA) 치료 시장 : 용도별

  • 주요 조사 결과
  • 서문
  • 소아
  • 성인

제7장 세계의 당뇨병성 케톤산증(DKA) 치료 시장 : 최종 사용자별

  • 주요 조사 결과
  • 서문
  • 전문 클리닉
  • 외래 진료 센터
  • 병원

제8장 세계의 당뇨병성 케톤산증(DKA) 치료 시장 : 지역별

  • 주요 조사 결과
  • 서문
    • 당뇨병성 케톤산증(DKA) 치료 시장 분석 : 지역별(2020-2034년)
  • 북미
    • 북미 : 치료 유형별(2020-2034년)
    • 북미 : 용도별(2020-2034년)
    • 북미 : 최종 사용자별(2020-2034년)
    • 미국
    • 캐나다
  • 유럽
    • 유럽 : 치료 유형별(2020-2034년)
    • 유럽 : 용도별(2020-2034년)
    • 유럽 : 최종 사용자별(2020-2034년)
    • 영국
    • 프랑스
    • 독일
    • 이탈리아
    • 스페인
    • 네덜란드
    • 러시아
    • 기타 유럽
  • 아시아태평양
    • 아시아태평양 : 치료 유형별(2020-2034년)
    • 아시아태평양 : 용도별(2020-2034년)
    • 아시아태평양 : 최종 사용자별(2020-2034년)
    • 중국
    • 인도
    • 말레이시아
    • 일본
    • 인도네시아
    • 한국
    • 호주
    • 기타 아시아태평양
  • 중동 및 아프리카
    • 중동 및 아프리카 : 치료 유형별(2020-2034년)
    • 중동 및 아프리카 : 용도별(2020-2034년)
    • 중동 및 아프리카 : 최종 사용자별(2020-2034년)
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이스라엘
    • 남아프리카
    • 기타 중동 및 아프리카
  • 라틴아메리카
    • 라틴아메리카 : 치료 유형별(2020-2034년)
    • 라틴아메리카 : 용도별(2020-2034년)
    • 라틴아메리카 : 최종 사용자별(2020-2034년)
    • 멕시코
    • 브라질
    • 아르헨티나
    • 기타 라틴아메리카

제9장 경쟁 구도

  • 확대 및 인수 분석
    • 확대
    • 인수
  • 제휴, 협업, 합의 및 공개

제10장 기업 프로파일

  • Abbott Laboratories
  • Becton, Dickinson and Company(BD)
  • Dexcom, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Glenmark Pharmaceuticals Ltd
  • Insulet Corporation
  • Medtronic plc
  • Novo Nordisk A/S
  • Sanofi
  • Tandem Diabetes Care, Inc.
  • Ypsomed AG
AJY 25.08.18

The diabetic ketoacidosis treatment market size is expected to reach USD 1,292.08 Million by 2034, according to a new study by Polaris Market Research. The report "Diabetic Ketoacidosis Treatment Market Share, Size, Trends, Industry Analysis Report: By Treatment Type, By Application (Pediatric and Adults), By End User, and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Diabetic ketoacidosis treatment is essential for correcting metabolic imbalance during acute diabetic emergencies in type 1 diabetes patients. Standard care includes intravenous insulin, fluid resuscitation and electrolyte replacement to stabilize hyperglycemia and acidosis. Advancements in insulin analogs, continuous glucose monitoring device and real-time electrolyte management are enhancing treatment outcomes across hospitals, ICUs and ambulatory care settings.

The growth of the diabetic ketoacidosis treatment market is primarily driven by the rising global prevalence of type 1 diabetes and increased adoption of digital health platforms in acute care settings. Additionally, the expansion of outpatient emergency infrastructure and payer-supported decentralized treatment models are accelerating adoption across developing and developed economies.

Diabetic Ketoacidosis Treatment Market Report Highlights

Based on treatment type, the insulin therapy dominated the market in 2024, owing to its continued use as the first-line intervention for rapid glucose reduction in emergency DKA protocols.

In terms of application, the adult segment dominated the market in 2024. This is driven by higher hospitalization rates linked to insulin omission, comorbidities, and delayed diabetes management in adult populations.

In terms of end user, the hospital segment dominated the market in 2024, owing to its comprehensive capacity to manage severe and recurrent DKA cases with access to advanced diagnostics, IV therapies and critical care staff.

North America accounted for the majority share of the global diabetic ketoacidosis treatment market in 2024, fueled by widespread CGM adoption, digital insulin delivery systems and adherence to standardized treatment protocols support market leadership.

Asia Pacific held significant market share, fueled by growing incidence of type 1 diabetes and public healthcare investments in emergency diabetic care.

A few global key market players include Novo Nordisk A/S, Sanofi, Eli Lilly and Company, Becton, Dickinson and Company (BD), Dexcom, Inc., Medtronic plc, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Insulet Corporation, Tandem Diabetes Care, Inc., Ypsomed AG, and Glenmark Pharmaceuticals Ltd.

Polaris Market Research has segmented the market report on the basis of treatment type, application, end user, and region:

By Treatment Type Outlook (Revenue, USD Million, 2020-2034)

Insulin Therapy

Fluid Replacement

Electrolyte Replacement

By Application Outlook (Revenue, USD Million, 2020-2034)

Pediatric

Adults

By End User Outlook (Revenue, USD Million, 2020-2034)

Specialty Clinics

Ambulatory Care Center

Hospitals

By Regional Outlook (Revenue, USD Million, 2020-2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Diabetic Ketoacidosis Treatment Market Insights

  • 4.1. Diabetic Ketoacidosis Treatment Market - Market Snapshot
  • 4.2. Diabetic Ketoacidosis Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Prevalence of Type 1 Diabetes Worldwide
      • 4.2.1.2. Integration of Digital Health Platforms in Acute Care Settings
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Cost Burden of Acute Care Infrastructure
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Diabetic Ketoacidosis Treatment Market Trends
  • 4.6. Value Chain Analysis

5. Global Diabetic Ketoacidosis Treatment Market, by Treatment Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
  • 5.3. Insulin Therapy
    • 5.3.1. Global Diabetic Ketoacidosis Treatment Market, by Insulin Therapy, by Region, 2020-2034 (USD Million)
  • 5.4. Fluid Replacement
    • 5.4.1. Global Diabetic Ketoacidosis Treatment Market, by Fluid Replacement, by Region, 2020-2034 (USD Million)
  • 5.5. Electrolyte Replacement
    • 5.5.1. Global Diabetic Ketoacidosis Treatment Market, by Electrolyte Replacement, by Region, 2020-2034 (USD Million)

6. Global Diabetic Ketoacidosis Treatment Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
  • 6.3. Pediatric
    • 6.3.1. Global Diabetic Ketoacidosis Treatment Market, by Pediatric, by Region, 2020-2034 (USD Million)
  • 6.4. Adults
    • 6.4.1. Global Diabetic Ketoacidosis Treatment Market, by Adults, by Region, 2020-2034 (USD Million)

7. Global Diabetic Ketoacidosis Treatment Market, by End User

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
  • 7.3. Specialty Clinics
    • 7.3.1. Global Diabetic Ketoacidosis Treatment Market, by Specialty Clinics, by Region, 2020-2034 (USD Million)
  • 7.4. Ambulatory Care Center
    • 7.4.1. Global Diabetic Ketoacidosis Treatment Market, by Ambulatory Care Center, by Region, 2020-2034 (USD Million)
  • 7.5. Hospitals
    • 7.5.1. Global Diabetic Ketoacidosis Treatment Market, by Hospitals, by Region, 2020-2034 (USD Million)

8. Global Diabetic Ketoacidosis Treatment Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Diabetic Ketoacidosis Treatment Market Assessment, By Geography, 2020-2034 (USD Million)
  • 8.3. Diabetic Ketoacidosis Treatment Market - North America
    • 8.3.1. North America: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
    • 8.3.2. North America: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
    • 8.3.3. North America: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.3.4. Diabetic Ketoacidosis Treatment Market - U.S.
      • 8.3.4.1. U.S.: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.3.4.2. U.S.: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.3.4.3. U.S.: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.3.5. Diabetic Ketoacidosis Treatment Market - Canada
      • 8.3.5.1. Canada: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.3.5.2. Canada: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.3.5.3. Canada: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
  • 8.4. Diabetic Ketoacidosis Treatment Market - Europe
    • 8.4.1. Europe: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
    • 8.4.2. Europe: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
    • 8.4.3. Europe: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.4.4. Diabetic Ketoacidosis Treatment Market - UK
      • 8.4.4.1. UK: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.4.4.2. UK: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.4.4.3. UK: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.4.5. Diabetic Ketoacidosis Treatment Market - France
      • 8.4.5.1. France: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.4.5.2. France: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.4.5.3. France: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.4.6. Diabetic Ketoacidosis Treatment Market - Germany
      • 8.4.6.1. Germany: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.4.6.2. Germany: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.4.6.3. Germany: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.4.7. Diabetic Ketoacidosis Treatment Market - Italy
      • 8.4.7.1. Italy: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.4.7.2. Italy: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.4.7.3. Italy: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.4.8. Diabetic Ketoacidosis Treatment Market - Spain
      • 8.4.8.1. Spain: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.4.8.2. Spain: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.4.8.3. Spain: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.4.9. Diabetic Ketoacidosis Treatment Market - Netherlands
      • 8.4.9.1. Netherlands: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.4.9.2. Netherlands: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.4.9.3. Netherlands: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.4.10. Diabetic Ketoacidosis Treatment Market - Russia
      • 8.4.10.1. Russia: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.4.10.2. Russia: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.4.10.3. Russia: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.4.11. Diabetic Ketoacidosis Treatment Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.4.11.2. Rest of Europe: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.4.11.3. Rest of Europe: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
  • 8.5. Diabetic Ketoacidosis Treatment Market - Asia Pacific
    • 8.5.1. Asia Pacific: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
    • 8.5.2. Asia Pacific: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
    • 8.5.3. Asia Pacific: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.5.4. Diabetic Ketoacidosis Treatment Market - China
      • 8.5.4.1. China: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.5.4.2. China: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.5.4.3. China: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.5.5. Diabetic Ketoacidosis Treatment Market - India
      • 8.5.5.1. India: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.5.5.2. India: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.5.5.3. India: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.5.6. Diabetic Ketoacidosis Treatment Market - Malaysia
      • 8.5.6.1. Malaysia: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.5.6.2. Malaysia: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.5.6.3. Malaysia: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.5.7. Diabetic Ketoacidosis Treatment Market - Japan
      • 8.5.7.1. Japan: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.5.7.2. Japan: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.5.7.3. Japan: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.5.8. Diabetic Ketoacidosis Treatment Market - Indonesia
      • 8.5.8.1. Indonesia: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.5.8.2. Indonesia: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.5.8.3. Indonesia: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.5.9. Diabetic Ketoacidosis Treatment Market - South Korea
      • 8.5.9.1. South Korea: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.5.9.2. South Korea: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.5.9.3. South Korea: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.5.10. Diabetic Ketoacidosis Treatment Market - Australia
      • 8.5.10.1. Australia: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.5.10.2. Australia: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.5.10.3. Australia: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.5.11. Diabetic Ketoacidosis Treatment Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.5.11.2. Rest of Asia Pacific: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.5.11.3. Rest of Asia Pacific: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
  • 8.6. Diabetic Ketoacidosis Treatment Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
    • 8.6.2. Middle East & Africa: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
    • 8.6.3. Middle East & Africa: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.6.4. Diabetic Ketoacidosis Treatment Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.6.4.2. Saudi Arabia: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.6.4.3. Saudi Arabia: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.6.5. Diabetic Ketoacidosis Treatment Market - UAE
      • 8.6.5.1. UAE: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.6.5.2. UAE: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.6.5.3. UAE: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.6.6. Diabetic Ketoacidosis Treatment Market - Israel
      • 8.6.6.1. Israel: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.6.6.2. Israel: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.6.6.3. Israel: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.6.7. Diabetic Ketoacidosis Treatment Market - South Africa
      • 8.6.7.1. South Africa: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.6.7.2. South Africa: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.6.7.3. South Africa: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.6.8. Diabetic Ketoacidosis Treatment Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.6.8.2. Rest of Middle East & Africa: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.6.8.3. Rest of Middle East & Africa: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
  • 8.7. Diabetic Ketoacidosis Treatment Market - Latin America
    • 8.7.1. Latin America: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
    • 8.7.2. Latin America: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
    • 8.7.3. Latin America: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.7.4. Diabetic Ketoacidosis Treatment Market - Mexico
      • 8.7.4.1. Mexico: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.7.4.2. Mexico: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.7.4.3. Mexico: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.7.5. Diabetic Ketoacidosis Treatment Market - Brazil
      • 8.7.5.1. Brazil: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.7.5.2. Brazil: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.7.5.3. Brazil: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.7.6. Diabetic Ketoacidosis Treatment Market - Argentina
      • 8.7.6.1. Argentina: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.7.6.2. Argentina: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.7.6.3. Argentina: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)
    • 8.7.7. Diabetic Ketoacidosis Treatment Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Diabetic Ketoacidosis Treatment Market, by Treatment Type, 2020-2034 (USD Million)
      • 8.7.7.2. Rest of Latin America: Diabetic Ketoacidosis Treatment Market, by Application, 2020-2034 (USD Million)
      • 8.7.7.3. Rest of Latin America: Diabetic Ketoacidosis Treatment Market, by End User, 2020-2034 (USD Million)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Abbott Laboratories
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Becton, Dickinson and Company (BD)
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Dexcom, Inc.
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Eli Lilly and Company
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. F. Hoffmann-La Roche Ltd
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Glenmark Pharmaceuticals Ltd
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Insulet Corporation
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Medtronic plc
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Novo Nordisk A/S
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Sanofi
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Tandem Diabetes Care, Inc.
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Ypsomed AG
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제